
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.

Your AI-Trained Oncology Knowledge Connection!


Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.

Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.

Eric J. Sherman, MD, highlights trends he observed with immunotherapy in the head and neck cancer space.

Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.

Published: July 17th 2021 | Updated:

Published: July 10th 2021 | Updated:

Published: July 16th 2021 | Updated:

Published: July 7th 2021 | Updated: